The Global Continuous Glucose Monitoring Systems Market is estimated to be USD 4.34 Bn in 2021 and is expected to reach USD 6.71 Bn by 2026, growing at a CAGR of 9.1%.
Moreover, the growing awareness of smart devices and digital platforms, increasing awareness and management of diabetes, creates opportunities for the continuous glucose monitoring market.
By Component, the market is classified into Transmitters & Receivers, Sensors, and Insulin Pumps. Amongst all, the sensors segment is estimated to hold the highest market share during the forecast period.
By End User, the market is classified as Hospitals, Home Care, Diagnostics Clinics, and others. Amongst all, the Hospitals segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
2. Tandem Diabetes Care Announces Commercial Launch of the t:slim X2 Insulin Pump with Control-IQ Technology in the United States. The system is integrated with Dexcom G6 continuous glucose monitoring. - 15th January 2020
Market Dynamics
Factors driving the continuous glucose monitoring market are the worldwide rise in the prevalence of diabetes, increasing demand for less minimally invasive or non-invasive diagnosis, and point-of-care devices. Additionally, increasing R&D investments by government and privately held companies are driving market’s growth. However, the high cost of the products, frequent product replacement and ineffective reimbursement, the strict regulations by the government, and safety issues are anticipated to hinder the market growth.Moreover, the growing awareness of smart devices and digital platforms, increasing awareness and management of diabetes, creates opportunities for the continuous glucose monitoring market.
Market Segmentation
The Global Continuous Glucose Monitoring Systems Market is segmented further based on Component, End User, and Geography.By Component, the market is classified into Transmitters & Receivers, Sensors, and Insulin Pumps. Amongst all, the sensors segment is estimated to hold the highest market share during the forecast period.
By End User, the market is classified as Hospitals, Home Care, Diagnostics Clinics, and others. Amongst all, the Hospitals segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
Recent Developments
1. Abbott received FDA approval for its FreeStyle Libre 3 system - diabetes device as an iCGM (integrated continuous glucose monitor). - 15th June 20202. Tandem Diabetes Care Announces Commercial Launch of the t:slim X2 Insulin Pump with Control-IQ Technology in the United States. The system is integrated with Dexcom G6 continuous glucose monitoring. - 15th January 2020
Company Profiles
Some of the companies covered in this report are Abbott Laboratories, AgaMatrix Inc, Bayer AG, DexCom, Inc, Echo Therapeutics, Inc., etc.Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.Why buy this report?
- The report offers a comprehensive evaluation of the Global Continuous Glucose Monitoring Systems Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
- The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
- The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Continuous Glucose Monitoring Systems Market
What is the estimated value of the Global Continuous Glucose Monitoring Systems Market?
What is the growth rate of the Global Continuous Glucose Monitoring Systems Market?
What is the forecasted size of the Global Continuous Glucose Monitoring Systems Market?
Who are the key companies in the Global Continuous Glucose Monitoring Systems Market?
Report Attribute | Details |
---|---|
No. of Pages | 178 |
Published | June 2021 |
Forecast Period | 2021 - 2026 |
Estimated Market Value ( USD
| USD 4340 Million |
Forecasted Market Value ( USD
| USD 6710 Million |
Compound Annual Growth Rate | 9.1% |
Regions Covered | Global |
No. of Companies Mentioned | 23 |
Table of Contents
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Influencers
5 Market Analysis
6 Global Continuous Glucose Monitoring Systems Market, By Component
7 Global Continuous Glucose Monitoring Systems Market, By End-Use
8 Global Continuous Glucose Monitoring Systems Market, By Geography
9 Competitive Landscape
10 Company Profiles
11 Appendix
Companies Mentioned
- Abbott Laboratories
- AgaMatrix Inc.
- Bayer AG
- DexCom, Inc.
- Echo Therapeutics, Inc.
- F. Hoffmann-La Roche Ltd.
- GlySens Incorporated
- Insulet Corporation
- Johnson & Johnson Services Inc.
- LifeScan Inc.
- Medtronic PLC
- Medtrum Technologies Inc.
- Menarini Diagnostics S.r.l.
- Nemaura Medical Inc.
- Novo Nordisk A/S
- NXP Semiconductors N.V.
- Senseonics Holdings, Inc.
- STMicroelectronics
- Tandem Diabetes Care, Inc.
- Texas Instruments Inc
- ViCentra B.V.
- WaveForm Technologies, Inc
- Ypsomed Group